---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-24-000030"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:26:26.556173+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Amneal beats Q2 estimates, raises FY guidance; FDA approves CREXONT for Parkinson's

## Summary
- Q2 net revenue $702M (+17% YoY); GAAP net income $6M ($0.02 diluted EPS).
- Adjusted EBITDA $162M (+11% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.
- Raising full-year 2024 guidance on broad-based growth across all segments.
- FDA approved CREXONT (carbidopa/levodopa) for Parkinson's disease; launch expected September 2024.
- Specialty revenue +7%, Generics +14% (driven by biosimilars), AvKARE +33%.

## SEC filing metadata
- accession: 0001723128-24-000030
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000030/0001723128-24-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000030/amrx-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-24-000030
- JSON: https://secwatch.observer/filing/0001723128-24-000030.json
- Plain text: https://secwatch.observer/filing/0001723128-24-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.